Evan Wang
Stock Analyst at Guggenheim
(0.11)
# 4,369
Out of 5,008 analysts
8
Total ratings
25%
Success rate
-31.19%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Evan Wang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MTSR Metsera | Maintains: Buy | $56 → $62 | $52.90 | +17.20% | 1 | Jun 10, 2025 | |
| SPRB Spruce Biosciences | Reiterates: Neutral | n/a | $182.60 | - | 3 | Dec 12, 2024 | |
| CVAC CureVac | Reiterates: Neutral | n/a | $5.43 | - | 1 | Apr 5, 2024 | |
| IVVD Invivyd | Upgrades: Buy | $9 | $1.63 | +452.15% | 1 | Apr 5, 2024 | |
| VALN Valneva SE | Maintains: Buy | $18 → $17 | $10.65 | +59.62% | 1 | Mar 22, 2024 | |
| MRNA Moderna | Initiates: Neutral | n/a | $27.34 | - | 1 | Apr 26, 2023 |
Metsera
Jun 10, 2025
Maintains: Buy
Price Target: $56 → $62
Current: $52.90
Upside: +17.20%
Spruce Biosciences
Dec 12, 2024
Reiterates: Neutral
Price Target: n/a
Current: $182.60
Upside: -
CureVac
Apr 5, 2024
Reiterates: Neutral
Price Target: n/a
Current: $5.43
Upside: -
Invivyd
Apr 5, 2024
Upgrades: Buy
Price Target: $9
Current: $1.63
Upside: +452.15%
Valneva SE
Mar 22, 2024
Maintains: Buy
Price Target: $18 → $17
Current: $10.65
Upside: +59.62%
Moderna
Apr 26, 2023
Initiates: Neutral
Price Target: n/a
Current: $27.34
Upside: -